Results 71 to 80 of about 13,441 (240)

Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B. [PDF]

, 2018
Disfiguring skin lesions caused by several species of the Leishmania parasite characterize cutaneous leishmaniasis (CL). Successful treatment of CL with intravenous (i.v.) liposomal amphotericin B (LAmB) relies on the presence of adequate antibiotic ...
Alavijeh, Mo, Croft, Simon L, Fortes Francisco, Amanda, Harris, Andy, Murdan, Sudaxshina, Van Bocxlaer, Katrien, Wijnant, Gert-Jan, Yardley, Vanessa   +7 more
core   +2 more sources

Treatment of mucocutaneous leishmaniasis – A systematic review

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 6, Page 763-773, June 2024.
Summary Mucocutaneous leishmaniasis is a severe infectious disease, predominantly endemic in Central and South America and is characterized by granulomatous, destructive mucosal lesions in the oral, nasal, and pharyngeal cavities. It is caused by protozoa of the genus Leishmania spp. transmitted to humans by sandflies.
Theresa Fischer, Marcellus Fischer, Sibylle Schliemann, Peter Elsner   +3 more
wiley   +1 more source

Determining Leishmania Infection Levels by Automatic Analysis of Microscopy Images [PDF]

arXiv, 2013
Analysis of microscopy images is one important tool in many fields of biomedical research, as it allows the quantification of a multitude of parameters at the cellular level. However, manual counting of these images is both tiring and unreliable and ultimately very time-consuming for biomedical researchers.
arxiv  

Behandlung der mukokutanen Leishmaniose – eine systematische Übersicht

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 6, Page 763-774, June 2024.
Zusammenfassung Die mukokutane Leishmaniose ist eine schwere Infektionskrankheit, die überwiegend in Zentral‐ und Südamerika endemisch ist und sich klinisch mit granulomatösen, destruierenden Schleimhautläsionen im Mund‐Nasen‐Rachenraum manifestiert. Sie wird durch Protozoen, Leishmania spp., ausgelöst, die durch Sandmücken auf den Menschen übertragen ...
Theresa Fischer, Marcellus Fischer, Sibylle Schliemann, Peter Elsner   +3 more
wiley   +1 more source

Drug resistance and treatment failure in leishmaniasis: A 21st century challenge [PDF]

, 2017
Reevaluation of treatment guidelines for Old and New World leishmaniasis is urgently needed on a global basis because treatment failure is an increasing problem.
Alicia Ponte-Sucre, Andrew W Pountain, Barbara Papadopoulou, Francisco Gamarro, Jean-Claude Dujardin, Michael P Barrett, Raquel García-Hernández, Rogelio López-Vélez, Roy Mwenechanya   +8 more
core   +3 more sources

Synthetic Biology in Leishmaniasis: Design,simulation and validation of constructed Genetic circuit [PDF]

arXiv, 2013
Building circuits and studying their behavior in cells is a major goal of systems and synthetic biology. Synthetic biology enables the precise control of cellular states for systems studies, the discovery of novel parts, control strategies, and interactions for the design of robust synthetic systems. To the best of our knowledge,there are no literature
arxiv  

Experimental structure based drug design (SBDD) applications for anti‐leishmanial drugs: A paradigm shift?

Medicinal Research Reviews, Volume 44, Issue 3, Page 1055-1120, May 2024.
Abstract Leishmaniasis is a group of neglected tropical diseases caused by at least 20 species of Leishmania protozoa, which are spread by the bite of infected sandflies. There are three main forms of the disease: cutaneous leishmaniasis (CL, the most common), visceral leishmaniasis (VL, also known as kala‐azar, the most serious), and mucocutaneous ...
Miguel Marín, Marta López, Laura Gallego‐Yerga, Raquel Álvarez, Rafael Peláez   +4 more
wiley   +1 more source

Efficacy of Paromomycin-Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. [PDF]

, 2017
The 4-aminoquinoline chloroquine (CQ) is clinically used in combination with doxycycline to cure chronic Q fever, as it enhances the activity of the antibiotic against the causative bacterium Coxiella burnetii residing within macrophage phagolysosomes ...
Croft, Simon L, Murdan, Sudaxshina, Van Bocxlaer, Katrien, Wijnant, Gert-Jan, Yardley, Vanessa   +4 more
core   +2 more sources

LeishIF4E2 is a cap‐binding protein that plays a role in Leishmania cell cycle progression

The FASEB Journal, Volume 38, Issue 1, 15 January 2024.
Proposed model for LeishIF4E2 function. LeishIF4E2 is a cap‐binding protein that interacts with the stem‐loop‐binding protein 2 (SLBP2) in Leishmania. SLBP2 in higher eukaryotes represses expression of histones that contain a specific stem‐loop structure in their 3′ UTRs. Expression of LeishIF4E2 is reduced in a hemizygous deletion mutant of Leishmania.
Nofar Baron, Rajaram Purushotham, Durgeshwar Pullaiahgari, Priyanka Bose, Raz Zarivach, Michal Shapira   +5 more
wiley   +1 more source

Disruption of Leishmania flagellum attachment zone architecture causes flagellum loss

Molecular Microbiology, Volume 121, Issue 1, Page 53-68, January 2024.
In Leishmania parasites the flagellum attachment zone (FAZ) is a complex multi‐domain cytoskeletal structure that determines cell morphogenesis and pathogenicity. We identified 27 FAZ proteins and showed that deletion of two FAZ proteins resulted in a reduced cell body size, and flagellum loss in some cells.
Clare Halliday, Laryssa Vanessa de Liz, Sue Vaughan, Jack D. Sunter   +3 more
wiley   +1 more source